Search results

dupilumab (Dupixent)

For treatment of moderate-to-severe atopic dermatitis.

dupilumab (Dupixent)

For the treatment of moderate-to-severe atopic dermatitis in adult and adolescents 12 years and older who are candidates for systemic therapy

dupilumab (Dupixent)

Treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.

dupilumab (Dupixent)

In adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.

dupilumab (Dupixent)

As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

dupilumab (Dupixent)

For treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

dupilumab (Dupixent)

Treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older whose disease is not adequately controlled with H1 antihistamine treatment.

dupilumab (Dupixent)

In adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment.

dupilumab (Dupixent)

As an add-on therapy with intranasal corticosteroids (INCS) for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy with systemic corticosteroids (SCS) and/or surgery do not provide adequate disease control.

February 2024 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, February 12) published advice on five medicines.

September 2018 decisions news release

The Scottish Medicines Consortium (SMC), has today (Monday 10 September) published advice accepting four new medicines for use by NHSScotland.

August 2025 decisions news release

April 2021 decisions news release

Advice on four new medicines for use in conditions including multiple myeloma and severe migraine has today (Monday 12 April) been published by the Scottish Medicines Consortium. A new medicine for Duchenne Muscular Dystrophy has now also been included in the ultra-orphan pathway.